Filing Flows › Indivior Pharmaceuticals (INDV) › Q1 2025
Indivior Pharmaceuticals (INDV) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Indivior Pharmaceuticals (INDV) reported revenue of $266M for the first quarter 2025 (Q1 2025), -6% from a year earlier and -11% from the quarter before. Operating margin was 24.8%, net earnings $47.0M (17.7% of revenue).
Indivior Pharmaceuticals, Q1 2025: revenue $266M (-6% year over year), operating margin 24.8%, net earnings $47.0M, operating cash flow $75.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $266M | -11% | -6% |
| Gross profit | $221M | -12% | -10% |
| Operating profit | $66.0M | +43% | -12% |
| Net earnings | $47.0M | +124% | -23% |
| Operating cash flow | $75.0M | — | — |
| Free cash flow | $70.0M | — | — |
What changed
Revenue was $266.0M in Q1 2025, down 6% year over year and down 11% from the previous quarter.
Gross margin was 83.1%, down 3.5 points from a year earlier. Operating profit was $66.0M, a 24.8% margin (down 1.6 points year over year). Operating expenses fell 9% while revenue fell 6%. Net earnings were $47.0M, down 23% year over year. The effective tax rate was 19.0%.
Operating cash flow was $75.0M, 160% of net earnings. Non-cash charges added back $5.0M of depreciation and amortization and $6.0M of share-based compensation. Working capital and other items added $17.0M. Capital expenditures of $5.0M left free cash flow of $70.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the first quarter 2025?
Indivior Pharmaceuticals (INDV) reported revenue of $266M for the first quarter 2025 (Q1 2025), -6% from a year earlier and -11% from the quarter before.
Was Indivior Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $66.0M (24.8% of revenue) and net earnings $47.0M.